Patent number: 11345957
Abstract: The present disclosure relates to methods for treating glioblastoma in a subject in need thereof using gene signatures in exosomal RNA derived from the subject. The gene signatures comprise: at least one of FAM229B, ZNF35, CTD-2647L4.4, CABP5, CYP20A1, CEP126, DTX2P1-UPK3BP1-PMS2P11, RP11-507K12.1, KRBA2, CALD1, LRFN1, RP2, SLC2A13, CDKL3, SLC8A3, ANTXR2, TIGD5, AC074289.1 RP11-932O9.7; at least one of tRNA-Lys-CTT-2-2, tRNA-Pro-AGG-2-7, LAMTOR2, RAD51AP1, DENND2A, A1BG, THSD1, CSF1, RP11-332M2.1, ZNF717, ZNF860, ORC6, Clorf50, PSPH, HIST1H4C, CYP2U1, THAP8, TMEM192, NAA20; or at least one of CREBBP, CXCR2 and S100A9. The treatment methods comprise measuring the expression level of at least one of the aforementioned genes in exosomal RNA from a subject and administering to the subject a glioblastoma treatment based on the expression level(s).
Type:
Grant
Filed:
July 18, 2018
Date of Patent:
May 31, 2022
Assignee:
Exosome Diagnostics, Inc.
Inventors:
Robert Kitchen, Michael Valentino, Johan Skog, Vasisht Tadigotla, Dalin Chan, Sudipto Chakrabortty, James Hurley
Publication number: 20210179587
Abstract: Novel compounds, compositions, and methods of using and preparing the same, which may be useful for treating alpha-1 antitrypsin deficiency (AATD).
Type:
Application
Filed:
October 4, 2019
Publication date:
June 17, 2021
Inventors:
Upul Keerthi BANDARAGE, Cavan McKeon BLIGH, Michael John BOYD, Diane M. BOUCHER, Michael Aaron BRODNEY, Veronique DAMAGNEZ, Lev Tyler DEWEY FANNING, Mary Elizabeth ECCLES, Robert Francis FIMOGNARI, JR., Kevin James GAGNON, Pedro M. GARCIA BARRANTES, Simon GIROUX, Ronald Lee GREY, JR., Amy Beth HALL, Sarah Carol HOOD, Dennis James HURLEY, Joshua Kennedy HUSSEY, Mac Arthur JOHNSON, JR., Peter JONES, Sarathy KESAVAN, Adam LOOKER, Brad D. MAXWELL, John Patrick MAXWELL, Ales MEDEK, Mettachit NAVAMAL, Philippe Marcel NUHANT, Setu RODAY, Stefanie ROEPER, Rupa SAWANT, Yi SHI, Rebecca Jane SWETT, Qing TANG, Timothy Lewis TAPLEY, Stephen A. THOMSON, Michael WALDO, Jinwang XU
Publication number: 20200361939
Abstract: The disclosure provides compounds useful for treating alpha-1 antitrypsin deficiency (AATD), according to formula (I): tautomers thereof, pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable salts of the tautomers, deuterated derivatives of the compounds, deuterated derivatives of the tautomers, and deuterated derivatives of the salts, solid forms of those compounds and processes for making those compounds.
Type:
Application
Filed:
May 13, 2020
Publication date:
November 19, 2020
Inventors:
Upul Keerthi BANDARAGE, Cavan McKeon BLIGH, Diane BOUCHER, Michael John BOYD, Michael Aaron BRODNEY, Michael Philip CLARK, Veronique DAMAGNEZ, Lev Tyler Dewey FANNING, Robert Francis FIMOGNARI, Gabrielle Simone FLEMING, Kevin James GAGNON, Pedro Manuel GARCIA BARRANTES, Robert Daniel GIACOMETTI, Simon GIROUX, Ronald Lee GREY, Jr., Samantha GUIDO, Amy Beth HALL, Sarah Carol HOOD, Dennis James HURLEY, Mac Arthur JOHNSON, Jr., Peter Jones, Sarathy KESAVAN, Mei-Hsiu LAI, Siying LIU, Adam LOOKER, Brad MAXWELL, John Patrick MAXWELL, Ales MEDEK, Philippe Marcel NUHANT, Kirk Alan OVERHOFF, Setu RODAY, Stefanie ROEPER, Steven M. RONKIN, Rupa SAWANT, Yi SHI, Muna SHRESTHA, Marisa SPOSATO, Kathy STAVROPOULOS, Rebecca Jane SWETT, Timothy Lewis TAPLEY, Qing TANG, Stephen THOMSON, Jinwang XU, Mariam ZAKY
